| Synonyms |
Rimactane; 3-[[(4-Methyl-1-piperazin-yl)imino]methyl]rifamycin; Abrifam; Eremfat; Famcin; NSC 113926; Rifa; Rifacap; Rifadin; Rifadine; Rifaldazine; Rifampicin SV; Rifamycin AMP; Rifaprodin; Rifoldin; Riforal; Rimactan; Rimactane; Rimapen; Sinerdol; Tubocin |
| IUPAC Name |
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate |
| Molecular Weight |
822.94 |
| Molecular Formula |
C43H58N4O12 |
| Canonical SMILES |
CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C |
| InChI |
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1 |
| InChIKey |
JQXXHWHPUNPDRT-WLSIYKJHSA-N |
| Boiling Point |
1004.42°C at 760 mmHg |
| Melting Point |
>180°C (dec.) |
| Flash Point |
561.3±34.3 °C |
| Purity |
98% |
| Density |
1.34 g/cm3 |
| Solubility |
Soluble in Chloroform, DMSO, Methanol |
| Appearance |
Brownish-red Crystalline Powder |
| Application |
Antibiotics, Antitubercular; enzyme inhibitors; leprostatic agents; nucleic acid synthesis inhibitors |
| Storage |
Store at RT |
| Complexity |
1620 |
| Exact Mass |
822.40512330 |
| Index Of Refraction |
1.613 |
| In Vitro |
Rifampicin (100 mg/mL) can block the functional activity of P-glycoprotein. Rifampicin is not a substract for P-glycoprotein.
The mechanism of rifampicin resistance is unassociated with the functional activity of P-glycoprotein. |
| In Vivo |
ifampicin (200, 400 mg/kg) can induce fatty liver at high concentration. Rifampicin (30 mg/kg, i.p.) treatment of S464P biofilms in vivo results in a slight decline, but earlier rebinds in bioluminescence from these catheters compared with the parental signal, whereas rifampicin has no affect on bioluminescence in mice infected with mutant H481Y. |
| PSA |
220.15000 |
| Target |
Bacterial; Influenza Virus; Antibiotic; Orthopoxvirus |
| Vapor Pressure |
0.0±0.3 mmHg at 25°C |
| XLogP3-AA |
4.9 |
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/13292-46-1.gif)
